Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

4(40.0%)

Phase 2

4(40.0%)

N/A

2(20.0%)

10Total

Phase 1(4)

Phase 2(4)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT05293249Phase 1Completed

dMAbs for Prevention of COVID-19

Role: collaborator

NCT05781542Phase 1Completed

Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV

Role: collaborator

NCT06789159Phase 1Recruiting

A Phase Ib Study of VK-2019 in Patients With Relapsed or Refractory EBV+ Diffuse Large B-cell Lymphomas (DLBCL)

Role: collaborator

NCT04480554Phase 2Recruiting

Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1

Role: collaborator

NCT01935089Phase 2Completed

Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV

Role: lead

NCT02227277Phase 2Unknown

Reducing Proviral HIV DNA With Interferon-a

Role: lead

NCT00051818Phase 1Completed

Immune and Viral Outcomes of HIV-1 Therapy Interruption

Role: lead

NCT00594880Phase 2Completed

Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection

Role: lead

NCT00100646Not ApplicableCompleted

Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa

Role: lead

NCT00988780Not ApplicableUnknown

Maraviroc (CCR5) Antagonism to Decrease the Incidence of the Immune Reconstitution Inflammatory Syndrome in HIV-Infected Patients

Role: collaborator

All 10 trials loaded